# Enhancement of in-Vitro GC Function in Patients With COPD

> **NCT00241631** · PHASE2 · COMPLETED · sponsor: **Imperial College London** · enrollment: 49 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** Fluticasone Propionate
- **DRUG:** placebo
- **DRUG:** Theophylline

## Key facts

- **NCT ID:** NCT00241631
- **Lead sponsor:** Imperial College London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2019-12-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00241631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00241631, "Enhancement of in-Vitro GC Function in Patients With COPD". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00241631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*